Article Versions Notes

Oluka GK, Sembera J, Katende JS, Ankunda V, Kato L, Kurshan A, Graham C, Seow J, Doores KJ, Malim MH, et al. Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort. Vaccines. 2025; 13(2):143. https://doi.org/10.3390/vaccines13020143

Oluka, Gerald Kevin, Jackson Sembera, Joseph Ssebwana Katende, Violet Ankunda, Laban Kato, Ashwini Kurshan, Carl Graham, Jeffrey Seow, Katie J. Doores, Michael H. Malim, and et al. 2025. "Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort" Vaccines 13, no. 2: 143. https://doi.org/10.3390/vaccines13020143

Oluka, G. K., Sembera, J., Katende, J. S., Ankunda, V., Kato, L., Kurshan, A., Graham, C., Seow, J., Doores, K. J., Malim, M. H., Fox, J. M., Kaleebu, P., & Serwanga, J. (2025). Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort. Vaccines, 13(2), 143. https://doi.org/10.3390/vaccines13020143